Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses

Antiviral Research

Volumn 72, Issue 1, 2006, Pages 60-67

  Naesens, Lieve ^a   Stephens, Chad E ^b   Andrei, Graciela ^a   Loregian, Arianna ^c   De Bolle, Leen ^a   Snoeck, Robert ^a   Sowell, J Walter ^b   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiviral; Arylsulfone derivative; Betaherpesvirus; Cytomegalovirus; Human herpesvirus 6

Indexed keywords

3 (4 CHLOROPHENYL) 3,4 DIHYDRO 1,4 BENZOTHIAZINE 2 CARBONITRILE 1,1 DIOXIDE; ANTIVIRUS AGENT; BENZENE DERIVATIVE; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; SULFONE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SYNTHESIS; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; HERPES; HERPES VIRUS; HUMAN; HUMAN BETAHERPES VIRUS; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FOSCARNET; HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HUMANS; SULFONES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6;

EID: 33747892854     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.013     Document Type: Article

References (32)

1. Baliah V., and Ananthapadmanabhan S. Synthesis of some benzothiamorpholine-I,I-dioxides. Ind. J. Chem. 10 (1972) 917-918
2. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
3. Brideau R.J., Knechtel M.L., Huang A., Vaillancourt V.A., Vera E.E., Oien N.L., Hopkins T.A., Wieber J.L., Wilkinson K.F., Rush B.D., Schwende F.J., and Wathen M.W. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. 54 (2002) 19-28
4. Cihlar T., Fuller M.D., and Cherrington J.M. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expr. Purif. 11 (1997) 209-218
5. Coen D.M., and Schaffer P.A. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2 (2003) 278-288
6. De Bolle L., Michel D., Mertens T., Manichanh C., Agut H., De Clercq E., and Naesens L. Role of the human herpesvirus 6 U69-encoded kinase in the phosphorylation of ganciclovir. Mol. Pharmacol. 62 (2002) 714-721
7. De Bolle L., Andrei G., Snoeck R., Zhang Y., Van Lommel A., Otto M., Bousseau A., Roy C., De Clercq E., and Naesens L. Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem. Pharmacol. 15 (2004) 325-336
8. De Bolle L., Manichanh C., Agut H., De Clercq E., and Naesens L. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res. 64 (2004) 17-25
9. De Bolle L., Naesens L., and De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin. Microbiol. Rev. 18 (2005) 217-245
10. Dominguez G., Black J.B., Stamey F.R., Inoue N., and Pellett P.E. Physical and genetic maps of the human herpesvirus 7 strain SB genome. Arch. Virol. 141 (1996) 2387-2408
11. Emery V.C. Progress in understanding cytomegalovirus drug resistance. J. Clin. Virol. 21 (2001) 223-228
12. Evers D.L., Komazin G., Ptak R.G., Shin D., Emmer B.T., Townsend L.B., and Drach J.C. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48 (2004) 3918-3927
13. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47 (1995) 331-385
14. Loregian A., Rigatti R., Murphy M., Schievano E., Palù G., and Marsden H.S. Inhibition of human cytomegalovirus (HCMV) DNA polymerase by C-terminal peptides from the UL54 subunit. J. Virol. 77 (2003) 8336-8344
15. Loregian A., Appleton B.A., Hogle J.M., and Coen D.M. Residues of human cytomegalovirus DNA polymerase catalytic subunit, UL54, that are necessary and sufficient for interaction with the accessory protein UL44. J. Virol. 78 (2004) 158-167
16. Mendez J.C., Dockrell D.H., Espy M.J., Smith T.F., Wilson J.A., Harmsen W.S., Ilstrup D., and Paya C.V. Human beta-herpesvirus interactions in solid organ transplant recipients. J. Infect. Dis. 183 (2001) 179-184
17. Monahan S.J., Grinstead L.A., Olivieri W., and Parris D.S. Interaction between the herpes simplex virus type 1 origin-binding and DNA polymerase accessory proteins. Virology 241 (1998) 122-130
18. Naesens L., De Bolle L., and De Clercq E. Antiviral activity of antiherpetic drugs in lymphoblast cells infected with HHV-6. In: Hommes O.R., Wekerle H., and Clanet M. (Eds). Genes and Viruses in Multiple Sclerosis (2001), Elsevier, Amsterdam 241-250
19. Neyts J., Naesens L., Ying C., De Bolle L., and De Clercq E. Anti-herpesvirus activity of (1′S,2′R)-9-[[1′2′-bis(hydroxymethyl)-cycloprop-1′-yl]methyl]guanine (A-5021) in vitro and in vivo. Antiviral Res. 49 (2001) 115-120
20. Nichols W.G., and Boeckh M. Recent advances in the therapy and prevention of CMV infections. J. Clin. Virol. 16 (2000) 25-40
21. Pilger B.D., Ciu C., and Coen D.M. Identification of a small molecule that inhibits herpes simplex virus DNA polymerase subunit interactions and viral replication. Chem. Biol. 11 (2004) 647-654
22. Silvestri R., De Martino G., La Regina G., Artico M., Massa S., Vargiu L., Mura M., Loi A.G., Marceddu T., and La Colla P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. 46 (2003) 2482-2493
23. Snoeck R., Andrei G., Bodaghi B., Lagneaux L., Daelemans D., De Clercq E., Neyts J., Schols D., Naesens L., Michelson S., Bron D., Otto M.J., Bousseau A., Nemecek C., and Roy C. 2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res. 55 (2002) 413-424
24. Stephens, C.E., 1998. Synthesis of heterocyclic-based diaryl and bicyclic sulfones as potential HIV-1 reverse transcriptase inhibitors. PhD Dissertation. College of Pharmacy, University of South Carolina, USA.
25. Stephens C.E., Felder T.M., Sowell J.W., Andrei G., Balzarini J., Snoeck R., and De Clercq E. Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones. Bioorg. Med. Chem. 9 (2001) 1123-1132
26. Stephens C.E., and Sowell J.W. Synthesis of novel heterocycles from 2-amino-3-(cyanomethylsulfonyl)thiophene. J. Heterocycl. Chem. 35 (1998) 927-931
27. Underwood M.R., Harvey R.J., Stanat S.C., Hemphill M.L., Miller T., Drach J.C., Townsend L.B., and Biron K.K. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72 (1998) 717-725
28. Wathen M.W. Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol. 12 (2002) 167-178
29. Witvrouw M., Arranz M.E., Pannecouque C., De Clercq R., Jonckheere H., Schmit J.-C., Vandamme A.-M., Diaz J.A., Ingate S.T., Desmyter J., Esnouf R., Van Meervelt L., Vega S., Balzarini J., and De Clercq E. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TDD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors with anti-HIV activity. Antimicrob. Agents Chemother. 42 (1998) 618-623
30. Zerr D.M., Gupta D., Huang M.L., Carter R., and Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34 (2002) 309-317
31. Zerr D.M., Corey L., Kim H.W., Huang M.L., Nguy L., and Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin. Infect. Dis. 40 (2005) 932-940
32. Zhang Y., Schols D., and De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res. 43 (1999) 23-35